Transgenic mice have emerged as powerful tools for use in biologic drug discovery based on their unique potential in producing fully human antibodies. The majority of fully human antibodies approved to date in the U.S. have emerged from one or the other transgenic mice platform.

Nona Biosciences’ biologic discovery programs are based on two proprietary transgenic mouse platforms for generating human therapeutic antibodies. The platforms have broad potential for generating both conventional as well as the Next-Gen biologics that are fully human, affinity matured with excellent solubility and developability.

The transgenic mouse platforms are:

HCAb's patented technology generates novel "heavy chain only" antibodies, which are about half the size of a typical IgG. These antibodies carry IgG-like PK properties and Fc-domain functions without the need for additional engineering or humanization. Lack of light chain also minimizes the problem of light chain mispairing and heterodimerization. These characteristics enable the development of products with attributes not achievable by conventional antibody platforms. In addition, various formats, including single-domain antibodies, bi- and multi-specifics, antibody-drug conjugates, CAR-Ts or VH domain-derived diagnostic or therapeutic products, are also achievable using this platform.